Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

We believe that Perrigo stock, a healthcare company that provides over-the-counter health and wellness solutions, is a good buying opportunity at the present time. PRGO stock trades near $45 currently and it is, in fact, down 24% from its pre-Covid high of $59 in February 2020 – just before the.

Perrigo Looks Attractive After The Recent Correction

Let's see if Perrigo Company plc (PRGO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Consider Perrigo (PRGO) Stock Now?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Why Is Perrigo (PRGO) Up 6.9% Since Last Earnings Report?

In its journey to become a consumer-led player, Perrigo has already achieved its long-term sales targets well ahead of the schedule. Partly helped by pandemic-driven changes to consumer habits, the highly profitable consumer business is boosting its contribution to the top-line.

Perrigo: Undervalued Transformation Deserves A Closer Look

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Perrigo Company (NASDAQ:PRGO).

Were These Hedge Funds Right About Perrigo Company (PRGO)?

Investors liked the company's third-quarter earnings results.

Why Perrigo Stock Jumped Today

Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales.

Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up

The healthcare company delivered both good news and bad news.

What to Like and Dislike in Perrigo's Q3 Results

Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2020 Results - Earnings Call Transcript

Perrigo (PRGO) delivered earnings and revenue surprises of 10.71% and -1.44%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Q3 Earnings Beat Estimates

DUBLIN, Nov. 4, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that the Irish High Court, which is a court of first instance, ruled that the issuance of the Notice of Amended Assessment by Irish Revenue in November 2018 did not violate the Company's legitimate...

Irish High Court Rules Perrigo's Legitimate Expectations Not Violated; Company Remains Committed To Vigorously Challenging The Notice Of Amended Assesment

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®, Iwostin®...

Perrigo Completes Acquisition Of Market-Leading OTC Self-Care Brands In Eastern Europe

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has been advised by the Irish High Court that the Court's decision on our pending Judicial Review case on whether to...

Perrigo Updates Earnings Conference Call Timing Scheduled For November 4, 2020, Due To Notification Of Judical Review Decision

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its third quarter financial results on Wednesday, November 4, 2020. The Company will also host a conference call...

Perrigo To Release Third Quarter 2020 Financial Results On November 4, 2020

Biogen

Bio-Rad Laboratories

CVS Health

Immunomedics

Livongo Health Inc

Moderna

Insulet

QuidelOrtho Corp

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Top Healthcare Stocks for October 2020

Perrigo Company plc shares PRGO, -0.16% slid 3% in premarket trade Thursday, after the company said it's voluntarily recalling albuterol sulfate inhalation aerosols over concerns that some may not dispense properly due to clogging.

Perrigo shares dip premarket on news to voluntarily recall albuterol sulfate inhalation aerosols due to clogging concerns

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S.

Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance

AstraZeneca

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

Why Is Perrigo (PRGO) Up 2.7% Since Last Earnings Report?

Perrigo Company plc (PRGO) CEO Murray Kessler on Q2 2020 Results - Earnings Call Transcript

Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

Perrigo (PRGO) delivered earnings and revenue surprises of 18.39% and -0.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Q2 Earnings Beat Estimates

Shares of Perrigo (NYSE:PRGO) rose 0.9% in pre-market trading after the company reported Q2 results.

News for Perrigo Stock (PRGO)